id	sid	tid	token	lemma	pos
cord-272015-1anph6qi	1	1	key	key	JJ
cord-272015-1anph6qi	1	2	:	:	:
cord-272015-1anph6qi	1	3	cord-272015	cord-272015	JJ
cord-272015-1anph6qi	1	4	-	-	HYPH
cord-272015-1anph6qi	1	5	1anph6qi	1anph6qi	CD
cord-272015-1anph6qi	1	6	authors	author	NNS
cord-272015-1anph6qi	1	7	:	:	:
cord-272015-1anph6qi	1	8	Dauby	Dauby	NNP
cord-272015-1anph6qi	1	9	,	,	,
cord-272015-1anph6qi	1	10	Nicolas	Nicolas	NNP
cord-272015-1anph6qi	1	11	;	;	:
cord-272015-1anph6qi	1	12	Bottieau	Bottieau	NNP
cord-272015-1anph6qi	1	13	,	,	,
cord-272015-1anph6qi	1	14	Emmanuel	Emmanuel	NNP
cord-272015-1anph6qi	2	1	title	title	NN
cord-272015-1anph6qi	2	2	:	:	:
cord-272015-1anph6qi	2	3	The	the	DT
cord-272015-1anph6qi	2	4	unfinished	unfinished	JJ
cord-272015-1anph6qi	2	5	story	story	NN
cord-272015-1anph6qi	2	6	of	of	IN
cord-272015-1anph6qi	2	7	hydroxychloroquine	hydroxychloroquine	NNP
cord-272015-1anph6qi	2	8	in	in	IN
cord-272015-1anph6qi	2	9	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	2	10	:	:	:
cord-272015-1anph6qi	2	11	the	the	DT
cord-272015-1anph6qi	2	12	right	right	JJ
cord-272015-1anph6qi	2	13	anti	anti	JJ
cord-272015-1anph6qi	2	14	-	-	JJ
cord-272015-1anph6qi	2	15	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	2	16	dose	dose	NN
cord-272015-1anph6qi	2	17	at	at	IN
cord-272015-1anph6qi	2	18	the	the	DT
cord-272015-1anph6qi	2	19	right	right	JJ
cord-272015-1anph6qi	2	20	moment	moment	NN
cord-272015-1anph6qi	2	21	?	?	.
cord-272015-1anph6qi	3	1	date	date	NN
cord-272015-1anph6qi	3	2	:	:	:
cord-272015-1anph6qi	3	3	2020	2020	CD
cord-272015-1anph6qi	3	4	-	-	SYM
cord-272015-1anph6qi	3	5	10	10	CD
cord-272015-1anph6qi	3	6	-	-	SYM
cord-272015-1anph6qi	3	7	17	17	CD
cord-272015-1anph6qi	3	8	journal	journal	NN
cord-272015-1anph6qi	3	9	:	:	:
cord-272015-1anph6qi	4	1	Int	Int	NNP
cord-272015-1anph6qi	4	2	J	J	NNP
cord-272015-1anph6qi	4	3	Infect	infect	VB
cord-272015-1anph6qi	4	4	Dis	Dis	NNP
cord-272015-1anph6qi	4	5	DOI	doi	NN
cord-272015-1anph6qi	4	6	:	:	:
cord-272015-1anph6qi	4	7	10.1016/	10.1016/	CD
cord-272015-1anph6qi	5	1	j.ijid.2020.10.032	j.ijid.2020.10.032	NNP
cord-272015-1anph6qi	5	2	sha	sha	XX
cord-272015-1anph6qi	5	3	:	:	:
cord-272015-1anph6qi	6	1	6b33212fc439d64a833e518385e4999e28ab3138	6b33212fc439d64a833e518385e4999e28ab3138	CD
cord-272015-1anph6qi	6	2	doc_id	doc_id	CD
cord-272015-1anph6qi	7	1	:	:	:
cord-272015-1anph6qi	7	2	272015	272015	CD
cord-272015-1anph6qi	7	3	cord_uid	cord_uid	NNS
cord-272015-1anph6qi	7	4	:	:	:
cord-272015-1anph6qi	8	1	1anph6qi	1anph6qi	CD
cord-272015-1anph6qi	9	1	nan	nan	NNP
cord-272015-1anph6qi	9	2	Dear	Dear	NNP
cord-272015-1anph6qi	9	3	Editor	Editor	NNP
cord-272015-1anph6qi	9	4	,	,	,
cord-272015-1anph6qi	9	5	Uncontrolled	uncontrolled	JJ
cord-272015-1anph6qi	9	6	inflammation	inflammation	NN
cord-272015-1anph6qi	9	7	,	,	,
cord-272015-1anph6qi	9	8	partly	partly	RB
cord-272015-1anph6qi	9	9	related	relate	VBN
cord-272015-1anph6qi	9	10	to	to	IN
cord-272015-1anph6qi	9	11	activated	activate	VBN
cord-272015-1anph6qi	9	12	macrophages	macrophage	NNS
cord-272015-1anph6qi	9	13	,	,	,
cord-272015-1anph6qi	9	14	is	be	VBZ
cord-272015-1anph6qi	9	15	widely	widely	RB
cord-272015-1anph6qi	9	16	recognized	recognize	VBN
cord-272015-1anph6qi	9	17	as	as	IN
cord-272015-1anph6qi	9	18	an	an	DT
cord-272015-1anph6qi	9	19	independent	independent	JJ
cord-272015-1anph6qi	9	20	cause	cause	NN
cord-272015-1anph6qi	9	21	of	of	IN
cord-272015-1anph6qi	9	22	clinical	clinical	JJ
cord-272015-1anph6qi	9	23	deterioration	deterioration	NN
cord-272015-1anph6qi	9	24	and	and	CC
cord-272015-1anph6qi	9	25	mortality	mortality	NN
cord-272015-1anph6qi	9	26	in	in	IN
cord-272015-1anph6qi	9	27	hospitalised	hospitalise	VBN
cord-272015-1anph6qi	9	28	patients	patient	NNS
cord-272015-1anph6qi	9	29	(	(	-LRB-
cord-272015-1anph6qi	9	30	Webb	Webb	NNP
cord-272015-1anph6qi	9	31	et	et	NNP
cord-272015-1anph6qi	9	32	al	al	NNP
cord-272015-1anph6qi	9	33	.	.	NNP
cord-272015-1anph6qi	9	34	;	;	:
cord-272015-1anph6qi	10	1	Del	Del	NNP
cord-272015-1anph6qi	10	2	Valle	Valle	NNP
cord-272015-1anph6qi	10	3	et	et	NNP
cord-272015-1anph6qi	10	4	al	al	NNP
cord-272015-1anph6qi	10	5	.	.	NNP
cord-272015-1anph6qi	10	6	2020	2020	CD
cord-272015-1anph6qi	10	7	)	)	-RRB-
cord-272015-1anph6qi	10	8	.	.	.
cord-272015-1anph6qi	11	1	Following	follow	VBG
cord-272015-1anph6qi	11	2	the	the	DT
cord-272015-1anph6qi	11	3	results	result	NNS
cord-272015-1anph6qi	11	4	of	of	IN
cord-272015-1anph6qi	11	5	the	the	DT
cord-272015-1anph6qi	11	6	RECOVERY	recovery	NN
cord-272015-1anph6qi	11	7	trial	trial	NN
cord-272015-1anph6qi	11	8	and	and	CC
cord-272015-1anph6qi	11	9	of	of	IN
cord-272015-1anph6qi	11	10	an	an	DT
cord-272015-1anph6qi	11	11	additional	additional	JJ
cord-272015-1anph6qi	11	12	meta	meta	JJ
cord-272015-1anph6qi	11	13	-	-	HYPH
cord-272015-1anph6qi	11	14	analysis	analysis	NN
cord-272015-1anph6qi	11	15	,	,	,
cord-272015-1anph6qi	11	16	corticosteroids	corticosteroid	NNS
cord-272015-1anph6qi	11	17	are	be	VBP
cord-272015-1anph6qi	11	18	now	now	RB
cord-272015-1anph6qi	11	19	recommended	recommend	VBN
cord-272015-1anph6qi	11	20	as	as	IN
cord-272015-1anph6qi	11	21	a	a	DT
cord-272015-1anph6qi	11	22	standard	standard	NN
cord-272015-1anph6qi	11	23	of	of	IN
cord-272015-1anph6qi	11	24	care	care	NN
cord-272015-1anph6qi	11	25	for	for	IN
cord-272015-1anph6qi	11	26	hospitalized	hospitalize	VBN
cord-272015-1anph6qi	11	27	patients	patient	NNS
cord-272015-1anph6qi	11	28	with	with	IN
cord-272015-1anph6qi	11	29	severe	severe	JJ
cord-272015-1anph6qi	11	30	and	and	CC
cord-272015-1anph6qi	11	31	critical	critical	JJ
cord-272015-1anph6qi	11	32	COVID-19	covid-19	NN
cord-272015-1anph6qi	11	33	(	(	-LRB-
cord-272015-1anph6qi	11	34	WHO	who	WP
cord-272015-1anph6qi	11	35	2020	2020	CD
cord-272015-1anph6qi	11	36	)	)	-RRB-
cord-272015-1anph6qi	11	37	.	.	.
cord-272015-1anph6qi	12	1	Importantly	importantly	RB
cord-272015-1anph6qi	12	2	,	,	,
cord-272015-1anph6qi	12	3	the	the	DT
cord-272015-1anph6qi	12	4	benefit	benefit	NN
cord-272015-1anph6qi	12	5	of	of	IN
cord-272015-1anph6qi	12	6	this	this	DT
cord-272015-1anph6qi	12	7	anti	anti	JJ
cord-272015-1anph6qi	12	8	-	-	JJ
cord-272015-1anph6qi	12	9	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	12	10	intervention	intervention	NN
cord-272015-1anph6qi	12	11	has	have	VBZ
cord-272015-1anph6qi	12	12	been	be	VBN
cord-272015-1anph6qi	12	13	observed	observe	VBN
cord-272015-1anph6qi	12	14	with	with	IN
cord-272015-1anph6qi	12	15	a	a	DT
cord-272015-1anph6qi	12	16	low	low	JJ
cord-272015-1anph6qi	12	17	dose	dose	NN
cord-272015-1anph6qi	12	18	of	of	IN
cord-272015-1anph6qi	12	19	dexamethasone	dexamethasone	NN
cord-272015-1anph6qi	12	20	,	,	,
cord-272015-1anph6qi	12	21	while	while	IN
cord-272015-1anph6qi	12	22	observational	observational	JJ
cord-272015-1anph6qi	12	23	studies	study	NNS
cord-272015-1anph6qi	12	24	using	use	VBG
cord-272015-1anph6qi	12	25	higher	high	JJR
cord-272015-1anph6qi	12	26	dosage	dosage	NN
cord-272015-1anph6qi	12	27	of	of	IN
cord-272015-1anph6qi	12	28	corticosteroids	corticosteroid	NNS
cord-272015-1anph6qi	12	29	have	have	VBP
cord-272015-1anph6qi	12	30	not	not	RB
cord-272015-1anph6qi	12	31	reported	report	VBN
cord-272015-1anph6qi	12	32	any	any	DT
cord-272015-1anph6qi	12	33	favourable	favourable	JJ
cord-272015-1anph6qi	12	34	effect	effect	NN
cord-272015-1anph6qi	12	35	on	on	IN
cord-272015-1anph6qi	12	36	mortality	mortality	NN
cord-272015-1anph6qi	12	37	(	(	-LRB-
cord-272015-1anph6qi	12	38	Hasan	Hasan	NNP
cord-272015-1anph6qi	12	39	et	et	NNP
cord-272015-1anph6qi	12	40	al	al	NNP
cord-272015-1anph6qi	12	41	.	.	NNP
cord-272015-1anph6qi	12	42	2020	2020	CD
cord-272015-1anph6qi	12	43	)	)	-RRB-
cord-272015-1anph6qi	12	44	.	.	.
cord-272015-1anph6qi	13	1	The	the	DT
cord-272015-1anph6qi	13	2	observation	observation	NN
cord-272015-1anph6qi	13	3	by	by	IN
cord-272015-1anph6qi	13	4	Lammers	Lammers	NNP
cord-272015-1anph6qi	13	5	et	et	NNP
cord-272015-1anph6qi	13	6	al	al	NNP
cord-272015-1anph6qi	13	7	(	(	-LRB-
cord-272015-1anph6qi	13	8	Lammers	Lammers	NNP
cord-272015-1anph6qi	13	9	et	et	NNP
cord-272015-1anph6qi	13	10	al	al	NNP
cord-272015-1anph6qi	13	11	.	.	.
cord-272015-1anph6qi	13	12	)	)	-RRB-
cord-272015-1anph6qi	14	1	that	that	DT
cord-272015-1anph6qi	14	2	early	early	JJ
cord-272015-1anph6qi	14	3	HCQ	HCQ	NNP
cord-272015-1anph6qi	14	4	treatment	treatment	NN
cord-272015-1anph6qi	14	5	after	after	IN
cord-272015-1anph6qi	14	6	admission	admission	NN
cord-272015-1anph6qi	14	7	at	at	IN
cord-272015-1anph6qi	14	8	low	low	JJ
cord-272015-1anph6qi	14	9	dosage	dosage	NN
cord-272015-1anph6qi	14	10	(	(	-LRB-
cord-272015-1anph6qi	14	11	2400	2400	CD
cord-272015-1anph6qi	14	12	mg	mg	NN
cord-272015-1anph6qi	14	13	in	in	IN
cord-272015-1anph6qi	14	14	total	total	NN
cord-272015-1anph6qi	14	15	)	)	-RRB-
cord-272015-1anph6qi	14	16	is	be	VBZ
cord-272015-1anph6qi	14	17	associated	associate	VBN
cord-272015-1anph6qi	14	18	with	with	IN
cord-272015-1anph6qi	14	19	lower	low	JJR
cord-272015-1anph6qi	14	20	risk	risk	NN
cord-272015-1anph6qi	14	21	of	of	IN
cord-272015-1anph6qi	14	22	admission	admission	NN
cord-272015-1anph6qi	14	23	in	in	IN
cord-272015-1anph6qi	14	24	intensive	intensive	JJ
cord-272015-1anph6qi	14	25	care	care	NN
cord-272015-1anph6qi	14	26	unit	unit	NN
cord-272015-1anph6qi	14	27	coincides	coincide	VBZ
cord-272015-1anph6qi	14	28	with	with	IN
cord-272015-1anph6qi	14	29	large	large	JJ
cord-272015-1anph6qi	14	30	observational	observational	JJ
cord-272015-1anph6qi	14	31	studies	study	NNS
cord-272015-1anph6qi	14	32	showing	show	VBG
cord-272015-1anph6qi	14	33	a	a	DT
cord-272015-1anph6qi	14	34	lower	low	JJR
cord-272015-1anph6qi	14	35	mortality	mortality	NN
cord-272015-1anph6qi	14	36	rate	rate	NN
cord-272015-1anph6qi	14	37	in	in	IN
cord-272015-1anph6qi	14	38	patients	patient	NNS
cord-272015-1anph6qi	14	39	exposed	expose	VBN
cord-272015-1anph6qi	14	40	to	to	IN
cord-272015-1anph6qi	14	41	HCQ	hcq	NN
cord-272015-1anph6qi	14	42	therapy	therapy	NN
cord-272015-1anph6qi	14	43	compared	compare	VBN
cord-272015-1anph6qi	14	44	to	to	IN
cord-272015-1anph6qi	14	45	no	no	DT
cord-272015-1anph6qi	14	46	or	or	CC
cord-272015-1anph6qi	14	47	other	other	JJ
cord-272015-1anph6qi	14	48	treatment	treatment	NN
cord-272015-1anph6qi	14	49	.	.	.
cord-272015-1anph6qi	15	1	Of	of	IN
cord-272015-1anph6qi	15	2	note	note	VB
cord-272015-1anph6qi	15	3	,	,	,
cord-272015-1anph6qi	15	4	in	in	IN
cord-272015-1anph6qi	15	5	all	all	PDT
cord-272015-1anph6qi	15	6	these	these	DT
cord-272015-1anph6qi	15	7	studies	study	NNS
cord-272015-1anph6qi	15	8	and	and	CC
cord-272015-1anph6qi	15	9	in	in	IN
cord-272015-1anph6qi	15	10	contrast	contrast	NN
cord-272015-1anph6qi	15	11	to	to	IN
cord-272015-1anph6qi	15	12	the	the	DT
cord-272015-1anph6qi	15	13	RECOVERY	recovery	NN
cord-272015-1anph6qi	15	14	trial	trial	NN
cord-272015-1anph6qi	15	15	,	,	,
cord-272015-1anph6qi	15	16	low	low	JJ
cord-272015-1anph6qi	15	17	doses	dose	NNS
cord-272015-1anph6qi	15	18	of	of	IN
cord-272015-1anph6qi	15	19	HCQ	HCQ	NNP
cord-272015-1anph6qi	15	20	(	(	-LRB-
cord-272015-1anph6qi	15	21	<	<	NNP
cord-272015-1anph6qi	15	22	2.5	2.5	CD
cord-272015-1anph6qi	15	23	gr	gr	NNP
cord-272015-1anph6qi	15	24	.	.	NNP
cord-272015-1anph6qi	15	25	in	in	IN
cord-272015-1anph6qi	15	26	total	total	NN
cord-272015-1anph6qi	15	27	)	)	-RRB-
cord-272015-1anph6qi	15	28	were	be	VBD
cord-272015-1anph6qi	15	29	used	use	VBN
cord-272015-1anph6qi	15	30	,	,	,
cord-272015-1anph6qi	15	31	often	often	RB
cord-272015-1anph6qi	15	32	soon	soon	RB
cord-272015-1anph6qi	15	33	after	after	IN
cord-272015-1anph6qi	15	34	admission	admission	NN
cord-272015-1anph6qi	15	35	(	(	-LRB-
cord-272015-1anph6qi	15	36	Arshad	Arshad	NNP
cord-272015-1anph6qi	15	37	et	et	NNP
cord-272015-1anph6qi	15	38	al	al	NNP
cord-272015-1anph6qi	15	39	.	.	.
cord-272015-1anph6qi	15	40	2020	2020	CD
cord-272015-1anph6qi	15	41	;	;	:
cord-272015-1anph6qi	15	42	Ayerbe	Ayerbe	NNP
cord-272015-1anph6qi	15	43	et	et	NNP
cord-272015-1anph6qi	15	44	al	al	NNP
cord-272015-1anph6qi	15	45	.	.	NNP
cord-272015-1anph6qi	15	46	2020	2020	CD
cord-272015-1anph6qi	15	47	;	;	:
cord-272015-1anph6qi	15	48	Catteau	Catteau	NNP
cord-272015-1anph6qi	15	49	et	et	NNP
cord-272015-1anph6qi	15	50	al	al	NNP
cord-272015-1anph6qi	15	51	.	.	NNP
cord-272015-1anph6qi	15	52	2020	2020	CD
cord-272015-1anph6qi	15	53	;	;	.
cord-272015-1anph6qi	16	1	COVID-19	covid-19	JJ
cord-272015-1anph6qi	16	2	RISK	RISK	NNP
cord-272015-1anph6qi	16	3	and	and	CC
cord-272015-1anph6qi	16	4	Treatments	Treatments	NNP
cord-272015-1anph6qi	16	5	(	(	-LRB-
cord-272015-1anph6qi	16	6	CORIST	CORIST	NNP
cord-272015-1anph6qi	16	7	)	)	-RRB-
cord-272015-1anph6qi	16	8	Collaboration	collaboration	NN
cord-272015-1anph6qi	16	9	2020	2020	CD
cord-272015-1anph6qi	16	10	)	)	-RRB-
cord-272015-1anph6qi	16	11	.	.	.
cord-272015-1anph6qi	17	1	Another	another	DT
cord-272015-1anph6qi	17	2	recent	recent	JJ
cord-272015-1anph6qi	17	3	large	large	JJ
cord-272015-1anph6qi	17	4	cohort	cohort	NN
cord-272015-1anph6qi	17	5	study	study	NN
cord-272015-1anph6qi	17	6	of	of	IN
cord-272015-1anph6qi	17	7	patients	patient	NNS
cord-272015-1anph6qi	17	8	on	on	IN
cord-272015-1anph6qi	17	9	low	low	JJ
cord-272015-1anph6qi	17	10	-	-	HYPH
cord-272015-1anph6qi	17	11	dose	dose	NN
cord-272015-1anph6qi	17	12	HCQ	HCQ	NNP
cord-272015-1anph6qi	17	13	for	for	IN
cord-272015-1anph6qi	17	14	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	17	15	disorders	disorder	NNS
cord-272015-1anph6qi	17	16	reported	report	VBD
cord-272015-1anph6qi	17	17	an	an	DT
cord-272015-1anph6qi	17	18	association	association	NN
cord-272015-1anph6qi	17	19	between	between	IN
cord-272015-1anph6qi	17	20	chronic	chronic	JJ
cord-272015-1anph6qi	17	21	HCQ	HCQ	NNP
cord-272015-1anph6qi	17	22	use	use	NN
cord-272015-1anph6qi	17	23	and	and	CC
cord-272015-1anph6qi	17	24	reduced	reduce	VBN
cord-272015-1anph6qi	17	25	mortality	mortality	NN
cord-272015-1anph6qi	17	26	following	follow	VBG
cord-272015-1anph6qi	17	27	SARS	SARS	NNP
cord-272015-1anph6qi	17	28	-	-	HYPH
cord-272015-1anph6qi	17	29	CoV-2	CoV-2	NNP
cord-272015-1anph6qi	17	30	infection	infection	NN
cord-272015-1anph6qi	18	1	(	(	-LRB-
cord-272015-1anph6qi	18	2	Gentry	Gentry	NNP
cord-272015-1anph6qi	18	3	et	et	NNP
cord-272015-1anph6qi	18	4	al	al	NNP
cord-272015-1anph6qi	18	5	.	.	NNP
cord-272015-1anph6qi	18	6	2020	2020	CD
cord-272015-1anph6qi	18	7	)	)	-RRB-
cord-272015-1anph6qi	18	8	.	.	.
cord-272015-1anph6qi	19	1	As	as	IN
cord-272015-1anph6qi	19	2	highlighted	highlight	VBN
cord-272015-1anph6qi	19	3	by	by	IN
cord-272015-1anph6qi	19	4	the	the	DT
cord-272015-1anph6qi	19	5	findings	finding	NNS
cord-272015-1anph6qi	19	6	of	of	IN
cord-272015-1anph6qi	19	7	Lammers	Lammers	NNP
cord-272015-1anph6qi	19	8	et	et	NNP
cord-272015-1anph6qi	19	9	al	al	NNP
cord-272015-1anph6qi	19	10	,	,	,
cord-272015-1anph6qi	19	11	the	the	DT
cord-272015-1anph6qi	19	12	timing	timing	NN
cord-272015-1anph6qi	19	13	of	of	IN
cord-272015-1anph6qi	19	14	HCQ	HCQ	NNP
cord-272015-1anph6qi	19	15	therapy	therapy	NN
cord-272015-1anph6qi	19	16	(	(	-LRB-
cord-272015-1anph6qi	19	17	administration	administration	NN
cord-272015-1anph6qi	19	18	within	within	IN
cord-272015-1anph6qi	19	19	1	1	CD
cord-272015-1anph6qi	19	20	day	day	NN
cord-272015-1anph6qi	19	21	of	of	IN
cord-272015-1anph6qi	19	22	admission	admission	NN
cord-272015-1anph6qi	19	23	)	)	-RRB-
cord-272015-1anph6qi	19	24	could	could	MD
cord-272015-1anph6qi	19	25	explain	explain	VB
cord-272015-1anph6qi	19	26	discrepancies	discrepancy	NNS
cord-272015-1anph6qi	19	27	between	between	IN
cord-272015-1anph6qi	19	28	different	different	JJ
cord-272015-1anph6qi	19	29	studies	study	NNS
cord-272015-1anph6qi	19	30	.	.	.
cord-272015-1anph6qi	20	1	In	in	IN
cord-272015-1anph6qi	20	2	the	the	DT
cord-272015-1anph6qi	20	3	RECOVERY	recovery	NN
cord-272015-1anph6qi	20	4	trial	trial	NN
cord-272015-1anph6qi	20	5	,	,	,
cord-272015-1anph6qi	20	6	the	the	DT
cord-272015-1anph6qi	20	7	median	median	JJ
cord-272015-1anph6qi	20	8	time	time	NN
cord-272015-1anph6qi	20	9	between	between	IN
cord-272015-1anph6qi	20	10	symptoms	symptom	NNS
cord-272015-1anph6qi	20	11	onset	onset	NN
cord-272015-1anph6qi	20	12	and	and	CC
cord-272015-1anph6qi	20	13	randomization	randomization	NN
cord-272015-1anph6qi	20	14	was	be	VBD
cord-272015-1anph6qi	20	15	9	9	CD
cord-272015-1anph6qi	20	16	days	day	NNS
cord-272015-1anph6qi	21	1	J	J	NNP
cord-272015-1anph6qi	21	2	o	o	NN
cord-272015-1anph6qi	21	3	u	u	NN
cord-272015-1anph6qi	21	4	r	r	NN
cord-272015-1anph6qi	21	5	n	n	NN
cord-272015-1anph6qi	21	6	a	a	DT
cord-272015-1anph6qi	21	7	l	l	NN
cord-272015-1anph6qi	21	8	P	p	NN
cord-272015-1anph6qi	21	9	r	r	NN
cord-272015-1anph6qi	21	10	e	e	NN
cord-272015-1anph6qi	21	11	-p	-p	NN
cord-272015-1anph6qi	22	1	r	r	NNP
cord-272015-1anph6qi	22	2	o	o	NN
cord-272015-1anph6qi	22	3	o	o	NN
cord-272015-1anph6qi	22	4	f	f	NN
cord-272015-1anph6qi	22	5	and	and	CC
cord-272015-1anph6qi	22	6	a	a	DT
cord-272015-1anph6qi	22	7	substantial	substantial	JJ
cord-272015-1anph6qi	22	8	proportion	proportion	NN
cord-272015-1anph6qi	22	9	of	of	IN
cord-272015-1anph6qi	22	10	patients	patient	NNS
cord-272015-1anph6qi	22	11	(	(	-LRB-
cord-272015-1anph6qi	22	12	16.7	16.7	CD
cord-272015-1anph6qi	22	13	%	%	NN
cord-272015-1anph6qi	22	14	)	)	-RRB-
cord-272015-1anph6qi	22	15	was	be	VBD
cord-272015-1anph6qi	22	16	already	already	RB
cord-272015-1anph6qi	22	17	on	on	IN
cord-272015-1anph6qi	22	18	mechanical	mechanical	JJ
cord-272015-1anph6qi	22	19	ventilation	ventilation	NN
cord-272015-1anph6qi	22	20	at	at	IN
cord-272015-1anph6qi	22	21	randomization(The	randomization(The	NNP
cord-272015-1anph6qi	22	22	RECOVERY	RECOVERY	NNP
cord-272015-1anph6qi	22	23	Collaborative	Collaborative	NNP
cord-272015-1anph6qi	22	24	Group	Group	NNP
cord-272015-1anph6qi	22	25	2020	2020	CD
cord-272015-1anph6qi	22	26	)	)	-RRB-
cord-272015-1anph6qi	22	27	.	.	.
cord-272015-1anph6qi	23	1	HCQ	HCQ	NNP
cord-272015-1anph6qi	23	2	has	have	VBZ
cord-272015-1anph6qi	23	3	been	be	VBN
cord-272015-1anph6qi	23	4	used	use	VBN
cord-272015-1anph6qi	23	5	as	as	IN
cord-272015-1anph6qi	23	6	anti	anti	JJ
cord-272015-1anph6qi	23	7	-	-	JJ
cord-272015-1anph6qi	23	8	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	23	9	drug	drug	NN
cord-272015-1anph6qi	23	10	for	for	IN
cord-272015-1anph6qi	23	11	decades	decade	NNS
cord-272015-1anph6qi	23	12	as	as	IN
cord-272015-1anph6qi	23	13	therapy	therapy	NN
cord-272015-1anph6qi	23	14	of	of	IN
cord-272015-1anph6qi	23	15	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	23	16	disorders	disorder	NNS
cord-272015-1anph6qi	23	17	and	and	CC
cord-272015-1anph6qi	23	18	its	-PRON-	PRP$
cord-272015-1anph6qi	23	19	impact	impact	NN
cord-272015-1anph6qi	23	20	on	on	IN
cord-272015-1anph6qi	23	21	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	23	22	responses	response	NNS
cord-272015-1anph6qi	23	23	is	be	VBZ
cord-272015-1anph6qi	23	24	well	well	RB
cord-272015-1anph6qi	23	25	documented	document	VBN
cord-272015-1anph6qi	23	26	.	.	.
cord-272015-1anph6qi	24	1	HCQ	HCQ	NNP
cord-272015-1anph6qi	24	2	inhibits	inhibit	VBZ
cord-272015-1anph6qi	24	3	the	the	DT
cord-272015-1anph6qi	24	4	production	production	NN
cord-272015-1anph6qi	24	5	of	of	IN
cord-272015-1anph6qi	24	6	the	the	DT
cord-272015-1anph6qi	24	7	pro	pro	JJ
cord-272015-1anph6qi	24	8	-	-	JJ
cord-272015-1anph6qi	24	9	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	24	10	cytokines	cytokine	NNS
cord-272015-1anph6qi	24	11	interleukin	interleukin	NN
cord-272015-1anph6qi	24	12	(	(	-LRB-
cord-272015-1anph6qi	24	13	IL)-6	IL)-6	NNP
cord-272015-1anph6qi	24	14	,	,	,
cord-272015-1anph6qi	24	15	TNF	TNF	NNP
cord-272015-1anph6qi	24	16	-	-	HYPH
cord-272015-1anph6qi	24	17	α	α	NNP
cord-272015-1anph6qi	24	18	and	and	CC
cord-272015-1anph6qi	24	19	IL-1-β	il-1-β	IN
cord-272015-1anph6qi	24	20	by	by	IN
cord-272015-1anph6qi	24	21	activated	activate	VBN
cord-272015-1anph6qi	24	22	macrophages	macrophage	NNS
cord-272015-1anph6qi	24	23	(	(	-LRB-
cord-272015-1anph6qi	24	24	Sperber	Sperber	NNP
cord-272015-1anph6qi	24	25	et	et	NNP
cord-272015-1anph6qi	24	26	al	al	NNP
cord-272015-1anph6qi	24	27	.	.	.
cord-272015-1anph6qi	24	28	1993	1993	CD
cord-272015-1anph6qi	25	1	;	;	:
cord-272015-1anph6qi	25	2	Jang	Jang	NNP
cord-272015-1anph6qi	25	3	et	et	FW
cord-272015-1anph6qi	25	4	al	al	NNP
cord-272015-1anph6qi	25	5	.	.	.
cord-272015-1anph6qi	25	6	2006	2006	CD
cord-272015-1anph6qi	25	7	)	)	-RRB-
cord-272015-1anph6qi	25	8	,	,	,
cord-272015-1anph6qi	25	9	which	which	WDT
cord-272015-1anph6qi	25	10	are	be	VBP
cord-272015-1anph6qi	25	11	notoriously	notoriously	RB
cord-272015-1anph6qi	25	12	associated	associate	VBN
cord-272015-1anph6qi	25	13	with	with	IN
cord-272015-1anph6qi	25	14	COVID-19	covid-19	JJ
cord-272015-1anph6qi	25	15	severity	severity	NN
cord-272015-1anph6qi	25	16	(	(	-LRB-
cord-272015-1anph6qi	25	17	Webb	Webb	NNP
cord-272015-1anph6qi	25	18	et	et	NNP
cord-272015-1anph6qi	25	19	al	al	NNP
cord-272015-1anph6qi	25	20	.	.	NNP
cord-272015-1anph6qi	25	21	;	;	:
cord-272015-1anph6qi	26	1	Del	Del	NNP
cord-272015-1anph6qi	26	2	Valle	Valle	NNP
cord-272015-1anph6qi	26	3	et	et	NNP
cord-272015-1anph6qi	26	4	al	al	NNP
cord-272015-1anph6qi	26	5	.	.	NNP
cord-272015-1anph6qi	26	6	2020	2020	CD
cord-272015-1anph6qi	26	7	)	)	-RRB-
cord-272015-1anph6qi	26	8	and	and	CC
cord-272015-1anph6qi	26	9	also	also	RB
cord-272015-1anph6qi	26	10	the	the	DT
cord-272015-1anph6qi	26	11	production	production	NN
cord-272015-1anph6qi	26	12	of	of	IN
cord-272015-1anph6qi	26	13	chemotactic	chemotactic	JJ
cord-272015-1anph6qi	26	14	cytokines	cytokine	NNS
cord-272015-1anph6qi	26	15	involved	involve	VBN
cord-272015-1anph6qi	26	16	in	in	IN
cord-272015-1anph6qi	26	17	the	the	DT
cord-272015-1anph6qi	26	18	recruitment	recruitment	NN
cord-272015-1anph6qi	26	19	of	of	IN
cord-272015-1anph6qi	26	20	pro	pro	JJ
cord-272015-1anph6qi	26	21	-	-	JJ
cord-272015-1anph6qi	26	22	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	26	23	cells	cell	NNS
cord-272015-1anph6qi	26	24	in	in	IN
cord-272015-1anph6qi	26	25	the	the	DT
cord-272015-1anph6qi	26	26	lungs(Grassin	lungs(Grassin	NNP
cord-272015-1anph6qi	26	27	-	-	HYPH
cord-272015-1anph6qi	26	28	Delyle	Delyle	NNP
cord-272015-1anph6qi	26	29	et	et	FW
cord-272015-1anph6qi	26	30	al	al	NNP
cord-272015-1anph6qi	26	31	.	.	NNP
cord-272015-1anph6qi	26	32	2020	2020	CD
cord-272015-1anph6qi	26	33	)	)	-RRB-
cord-272015-1anph6qi	26	34	.	.	.
cord-272015-1anph6qi	27	1	In	in	IN
cord-272015-1anph6qi	27	2	line	line	NN
cord-272015-1anph6qi	27	3	with	with	IN
cord-272015-1anph6qi	27	4	this	this	DT
cord-272015-1anph6qi	27	5	,	,	,
cord-272015-1anph6qi	27	6	an	an	DT
cord-272015-1anph6qi	27	7	Italian	italian	JJ
cord-272015-1anph6qi	27	8	study	study	NN
cord-272015-1anph6qi	27	9	suggests	suggest	VBZ
cord-272015-1anph6qi	27	10	that	that	IN
cord-272015-1anph6qi	27	11	the	the	DT
cord-272015-1anph6qi	27	12	benefit	benefit	NN
cord-272015-1anph6qi	27	13	of	of	IN
cord-272015-1anph6qi	27	14	HCQ	HCQ	NNP
cord-272015-1anph6qi	27	15	was	be	VBD
cord-272015-1anph6qi	27	16	restricted	restrict	VBN
cord-272015-1anph6qi	27	17	to	to	IN
cord-272015-1anph6qi	27	18	patients	patient	NNS
cord-272015-1anph6qi	27	19	with	with	IN
cord-272015-1anph6qi	27	20	elevated	elevated	JJ
cord-272015-1anph6qi	27	21	C	c	NN
cord-272015-1anph6qi	27	22	-	-	HYPH
cord-272015-1anph6qi	27	23	reactive	reactive	JJ
cord-272015-1anph6qi	27	24	protein	protein	NN
cord-272015-1anph6qi	27	25	levels(COVID-19	levels(covid-19	JJ
cord-272015-1anph6qi	27	26	RISK	risk	NN
cord-272015-1anph6qi	27	27	and	and	CC
cord-272015-1anph6qi	27	28	Treatments	Treatments	NNP
cord-272015-1anph6qi	27	29	(	(	-LRB-
cord-272015-1anph6qi	27	30	CORIST	CORIST	NNP
cord-272015-1anph6qi	27	31	)	)	-RRB-
cord-272015-1anph6qi	27	32	Collaboration	collaboration	NN
cord-272015-1anph6qi	27	33	2020	2020	CD
cord-272015-1anph6qi	27	34	)	)	-RRB-
cord-272015-1anph6qi	27	35	.	.	.
cord-272015-1anph6qi	28	1	Thrombotic	thrombotic	JJ
cord-272015-1anph6qi	28	2	events	event	NNS
cord-272015-1anph6qi	28	3	are	be	VBP
cord-272015-1anph6qi	28	4	another	another	DT
cord-272015-1anph6qi	28	5	well	well	RB
cord-272015-1anph6qi	28	6	recognized	recognize	VBN
cord-272015-1anph6qi	28	7	complication	complication	NN
cord-272015-1anph6qi	28	8	of	of	IN
cord-272015-1anph6qi	28	9	severe	severe	JJ
cord-272015-1anph6qi	28	10	COVID-19	covid-19	NN
cord-272015-1anph6qi	28	11	(	(	-LRB-
cord-272015-1anph6qi	28	12	Llitjos	Llitjos	NNP
cord-272015-1anph6qi	28	13	et	et	NNP
cord-272015-1anph6qi	28	14	al	al	NNP
cord-272015-1anph6qi	28	15	.	.	NNP
cord-272015-1anph6qi	28	16	2020	2020	CD
cord-272015-1anph6qi	28	17	)	)	-RRB-
cord-272015-1anph6qi	29	1	and	and	CC
cord-272015-1anph6qi	29	2	the	the	DT
cord-272015-1anph6qi	29	3	presence	presence	NN
cord-272015-1anph6qi	29	4	of	of	IN
cord-272015-1anph6qi	29	5	lupus	lupus	NN
cord-272015-1anph6qi	29	6	anticoagulant	anticoagulant	NN
cord-272015-1anph6qi	29	7	has	have	VBZ
cord-272015-1anph6qi	29	8	been	be	VBN
cord-272015-1anph6qi	29	9	reported	report	VBN
cord-272015-1anph6qi	29	10	in	in	IN
cord-272015-1anph6qi	29	11	hospitalised	hospitalise	VBN
cord-272015-1anph6qi	29	12	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	29	13	(	(	-LRB-
cord-272015-1anph6qi	29	14	Bowles	Bowles	NNP
cord-272015-1anph6qi	29	15	et	et	NNP
cord-272015-1anph6qi	29	16	al	al	NNP
cord-272015-1anph6qi	29	17	.	.	NNP
cord-272015-1anph6qi	29	18	2020	2020	CD
cord-272015-1anph6qi	29	19	)	)	-RRB-
cord-272015-1anph6qi	29	20	.	.	.
cord-272015-1anph6qi	30	1	HCQ	hcq	NN
cord-272015-1anph6qi	30	2	therapy	therapy	NN
cord-272015-1anph6qi	30	3	has	have	VBZ
cord-272015-1anph6qi	30	4	been	be	VBN
cord-272015-1anph6qi	30	5	associated	associate	VBN
cord-272015-1anph6qi	30	6	with	with	IN
cord-272015-1anph6qi	30	7	a	a	DT
cord-272015-1anph6qi	30	8	decrease	decrease	NN
cord-272015-1anph6qi	30	9	of	of	IN
cord-272015-1anph6qi	30	10	lupus	lupus	NN
cord-272015-1anph6qi	30	11	anticoagulant	anticoagulant	JJ
cord-272015-1anph6qi	30	12	levels	level	NNS
cord-272015-1anph6qi	30	13	as	as	RB
cord-272015-1anph6qi	30	14	well	well	RB
cord-272015-1anph6qi	30	15	as	as	IN
cord-272015-1anph6qi	30	16	of	of	IN
cord-272015-1anph6qi	30	17	platelet	platelet	NN
cord-272015-1anph6qi	30	18	activation	activation	NN
cord-272015-1anph6qi	30	19	and	and	CC
cord-272015-1anph6qi	30	20	thrombotic	thrombotic	JJ
cord-272015-1anph6qi	30	21	events	event	NNS
cord-272015-1anph6qi	30	22	in	in	IN
cord-272015-1anph6qi	30	23	lupus	lupus	NN
cord-272015-1anph6qi	30	24	patients	patient	NNS
cord-272015-1anph6qi	30	25	(	(	-LRB-
cord-272015-1anph6qi	30	26	Broder	Broder	NNP
cord-272015-1anph6qi	30	27	and	and	CC
cord-272015-1anph6qi	30	28	Putterman	Putterman	NNP
cord-272015-1anph6qi	30	29	2013	2013	CD
cord-272015-1anph6qi	30	30	)	)	-RRB-
cord-272015-1anph6qi	30	31	.	.	.
cord-272015-1anph6qi	31	1	Interestingly	interestingly	RB
cord-272015-1anph6qi	31	2	,	,	,
cord-272015-1anph6qi	31	3	B	b	NN
cord-272015-1anph6qi	31	4	cell	cell	NN
cord-272015-1anph6qi	31	5	abnormalities	abnormality	NNS
cord-272015-1anph6qi	31	6	similar	similar	JJ
cord-272015-1anph6qi	31	7	to	to	IN
cord-272015-1anph6qi	31	8	those	those	DT
cord-272015-1anph6qi	31	9	reported	report	VBN
cord-272015-1anph6qi	31	10	in	in	IN
cord-272015-1anph6qi	31	11	autoimmune	autoimmune	JJ
cord-272015-1anph6qi	31	12	disease	disease	NN
cord-272015-1anph6qi	31	13	such	such	JJ
cord-272015-1anph6qi	31	14	as	as	IN
cord-272015-1anph6qi	31	15	active	active	JJ
cord-272015-1anph6qi	31	16	lupus	lupus	NN
cord-272015-1anph6qi	31	17	were	be	VBD
cord-272015-1anph6qi	31	18	reported	report	VBN
cord-272015-1anph6qi	31	19	in	in	IN
cord-272015-1anph6qi	31	20	patients	patient	NNS
cord-272015-1anph6qi	31	21	with	with	IN
cord-272015-1anph6qi	31	22	severe	severe	JJ
cord-272015-1anph6qi	31	23	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	31	24	(	(	-LRB-
cord-272015-1anph6qi	31	25	Woodruff	Woodruff	NNP
cord-272015-1anph6qi	31	26	et	et	NNP
cord-272015-1anph6qi	31	27	al	al	NNP
cord-272015-1anph6qi	31	28	.	.	NNP
cord-272015-1anph6qi	31	29	2020	2020	CD
cord-272015-1anph6qi	31	30	)	)	-RRB-
cord-272015-1anph6qi	31	31	.	.	.
cord-272015-1anph6qi	32	1	HCQ	HCQ	NNP
cord-272015-1anph6qi	32	2	has	have	VBZ
cord-272015-1anph6qi	32	3	no	no	DT
cord-272015-1anph6qi	32	4	antiviral	antiviral	JJ
cord-272015-1anph6qi	32	5	activity	activity	NN
cord-272015-1anph6qi	32	6	in	in	IN
cord-272015-1anph6qi	32	7	vivo	vivo	NN
cord-272015-1anph6qi	32	8	against	against	IN
cord-272015-1anph6qi	32	9	SARS	SARS	NNP
cord-272015-1anph6qi	32	10	-	-	HYPH
cord-272015-1anph6qi	32	11	CoV-2	CoV-2	NNP
cord-272015-1anph6qi	32	12	as	as	IN
cord-272015-1anph6qi	32	13	shown	show	VBN
cord-272015-1anph6qi	32	14	in	in	IN
cord-272015-1anph6qi	32	15	pre	pre	JJ
cord-272015-1anph6qi	32	16	-	-	JJ
cord-272015-1anph6qi	32	17	clinical	clinical	JJ
cord-272015-1anph6qi	32	18	models	model	NNS
cord-272015-1anph6qi	32	19	such	such	JJ
cord-272015-1anph6qi	32	20	as	as	IN
cord-272015-1anph6qi	32	21	Syrian	syrian	JJ
cord-272015-1anph6qi	32	22	hamsters	hamster	NNS
cord-272015-1anph6qi	32	23	,	,	,
cord-272015-1anph6qi	32	24	non	non	JJ
cord-272015-1anph6qi	32	25	-	-	JJ
cord-272015-1anph6qi	32	26	human	human	JJ
cord-272015-1anph6qi	32	27	primates	primate	NNS
cord-272015-1anph6qi	32	28	and	and	CC
cord-272015-1anph6qi	32	29	human	human	JJ
cord-272015-1anph6qi	32	30	lung	lung	NN
cord-272015-1anph6qi	32	31	cells	cell	NNS
cord-272015-1anph6qi	32	32	,	,	,
cord-272015-1anph6qi	32	33	and	and	CC
cord-272015-1anph6qi	32	34	should	should	MD
cord-272015-1anph6qi	32	35	therefore	therefore	RB
cord-272015-1anph6qi	32	36	not	not	RB
cord-272015-1anph6qi	32	37	be	be	VB
cord-272015-1anph6qi	32	38	used	use	VBN
cord-272015-1anph6qi	32	39	as	as	IN
cord-272015-1anph6qi	32	40	antiviral	antiviral	JJ
cord-272015-1anph6qi	32	41	therapy	therapy	NN
cord-272015-1anph6qi	32	42	in	in	IN
cord-272015-1anph6qi	32	43	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	32	44	(	(	-LRB-
cord-272015-1anph6qi	32	45	Maisonnasse	Maisonnasse	NNP
cord-272015-1anph6qi	32	46	et	et	FW
cord-272015-1anph6qi	32	47	al	al	NNP
cord-272015-1anph6qi	32	48	.	.	NNP
cord-272015-1anph6qi	32	49	2020	2020	CD
cord-272015-1anph6qi	32	50	)	)	-RRB-
cord-272015-1anph6qi	32	51	.	.	.
cord-272015-1anph6qi	33	1	However	however	RB
cord-272015-1anph6qi	33	2	,	,	,
cord-272015-1anph6qi	33	3	to	to	TO
cord-272015-1anph6qi	33	4	further	further	RB
cord-272015-1anph6qi	33	5	understand	understand	VB
cord-272015-1anph6qi	33	6	the	the	DT
cord-272015-1anph6qi	33	7	positive	positive	JJ
cord-272015-1anph6qi	33	8	effects	effect	NNS
cord-272015-1anph6qi	33	9	observed	observe	VBN
cord-272015-1anph6qi	33	10	in	in	IN
cord-272015-1anph6qi	33	11	large	large	JJ
cord-272015-1anph6qi	33	12	observational	observational	JJ
cord-272015-1anph6qi	33	13	studies	study	NNS
cord-272015-1anph6qi	33	14	that	that	WDT
cord-272015-1anph6qi	33	15	used	use	VBD
cord-272015-1anph6qi	33	16	HCQ	HCQ	NNP
cord-272015-1anph6qi	33	17	offlabel	offlabel	NN
cord-272015-1anph6qi	33	18	in	in	IN
cord-272015-1anph6qi	33	19	the	the	DT
cord-272015-1anph6qi	33	20	early	early	JJ
cord-272015-1anph6qi	33	21	months	month	NNS
cord-272015-1anph6qi	33	22	of	of	IN
cord-272015-1anph6qi	33	23	the	the	DT
cord-272015-1anph6qi	33	24	pandemic	pandemic	NN
cord-272015-1anph6qi	33	25	,	,	,
cord-272015-1anph6qi	33	26	the	the	DT
cord-272015-1anph6qi	33	27	hypothesis	hypothesis	NN
cord-272015-1anph6qi	33	28	of	of	IN
cord-272015-1anph6qi	33	29	an	an	DT
cord-272015-1anph6qi	33	30	anti	anti	JJ
cord-272015-1anph6qi	33	31	-	-	JJ
cord-272015-1anph6qi	33	32	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	33	33	action	action	NN
cord-272015-1anph6qi	33	34	J	J	NNP
cord-272015-1anph6qi	33	35	o	o	NN
cord-272015-1anph6qi	33	36	u	u	NN
cord-272015-1anph6qi	33	37	r	r	NN
cord-272015-1anph6qi	33	38	n	n	NN
cord-272015-1anph6qi	33	39	a	a	DT
cord-272015-1anph6qi	33	40	l	l	NN
cord-272015-1anph6qi	33	41	P	p	NN
cord-272015-1anph6qi	33	42	r	r	NN
cord-272015-1anph6qi	33	43	e	e	NN
cord-272015-1anph6qi	33	44	-p	-p	NN
cord-272015-1anph6qi	33	45	r	r	NN
cord-272015-1anph6qi	33	46	o	o	NN
cord-272015-1anph6qi	33	47	o	o	NN
cord-272015-1anph6qi	33	48	f	f	NN
cord-272015-1anph6qi	33	49	4	4	CD
cord-272015-1anph6qi	33	50	should	should	MD
cord-272015-1anph6qi	33	51	not	not	RB
cord-272015-1anph6qi	33	52	be	be	VB
cord-272015-1anph6qi	33	53	discarded	discard	VBN
cord-272015-1anph6qi	33	54	.	.	.
cord-272015-1anph6qi	34	1	We	-PRON-	PRP
cord-272015-1anph6qi	34	2	suggest	suggest	VBP
cord-272015-1anph6qi	34	3	that	that	IN
cord-272015-1anph6qi	34	4	ongoing	ongoing	JJ
cord-272015-1anph6qi	34	5	trials	trial	NNS
cord-272015-1anph6qi	34	6	evaluating	evaluate	VBG
cord-272015-1anph6qi	34	7	HCQ	HCQ	NNP
cord-272015-1anph6qi	34	8	specifically	specifically	RB
cord-272015-1anph6qi	34	9	look	look	VB
cord-272015-1anph6qi	34	10	at	at	IN
cord-272015-1anph6qi	34	11	its	-PRON-	PRP$
cord-272015-1anph6qi	34	12	effect	effect	NN
cord-272015-1anph6qi	34	13	on	on	IN
cord-272015-1anph6qi	34	14	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	34	15	parameters	parameter	NNS
cord-272015-1anph6qi	34	16	with	with	IN
cord-272015-1anph6qi	34	17	add	add	VB
cord-272015-1anph6qi	34	18	-	-	HYPH
cord-272015-1anph6qi	34	19	on	on	RP
cord-272015-1anph6qi	34	20	studies	study	NNS
cord-272015-1anph6qi	34	21	if	if	IN
cord-272015-1anph6qi	34	22	necessary	necessary	JJ
cord-272015-1anph6qi	34	23	.	.	.
cord-272015-1anph6qi	35	1	In	in	IN
cord-272015-1anph6qi	35	2	the	the	DT
cord-272015-1anph6qi	35	3	same	same	JJ
cord-272015-1anph6qi	35	4	line	line	NN
cord-272015-1anph6qi	35	5	,	,	,
cord-272015-1anph6qi	35	6	ongoing	ongoing	JJ
cord-272015-1anph6qi	35	7	trials	trial	NNS
cord-272015-1anph6qi	35	8	are	be	VBP
cord-272015-1anph6qi	35	9	investigating	investigate	VBG
cord-272015-1anph6qi	35	10	colchicine	colchicine	NNP
cord-272015-1anph6qi	35	11	to	to	TO
cord-272015-1anph6qi	35	12	prevent	prevent	VB
cord-272015-1anph6qi	35	13	hospitalisation	hospitalisation	NN
cord-272015-1anph6qi	35	14	in	in	IN
cord-272015-1anph6qi	35	15	SARS	SARS	NNP
cord-272015-1anph6qi	35	16	-	-	HYPH
cord-272015-1anph6qi	35	17	CoV-2	CoV-2	NNP
cord-272015-1anph6qi	35	18	infected	infected	JJ
cord-272015-1anph6qi	35	19	subjects	subject	NNS
cord-272015-1anph6qi	35	20	,	,	,
cord-272015-1anph6qi	35	21	and	and	CC
cord-272015-1anph6qi	35	22	the	the	DT
cord-272015-1anph6qi	35	23	rationale	rationale	NN
cord-272015-1anph6qi	35	24	is	be	VBZ
cord-272015-1anph6qi	35	25	based	base	VBN
cord-272015-1anph6qi	35	26	on	on	IN
cord-272015-1anph6qi	35	27	anti	anti	JJ
cord-272015-1anph6qi	35	28	-	-	JJ
cord-272015-1anph6qi	35	29	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	35	30	properties	property	NNS
cord-272015-1anph6qi	35	31	,	,	,
cord-272015-1anph6qi	35	32	that	that	WDT
cord-272015-1anph6qi	35	33	are	be	VBP
cord-272015-1anph6qi	35	34	partly	partly	RB
cord-272015-1anph6qi	35	35	shared	share	VBN
cord-272015-1anph6qi	35	36	 	 	_SP
cord-272015-1anph6qi	35	37	Treatment	Treatment	NNP
cord-272015-1anph6qi	35	38	with	with	IN
cord-272015-1anph6qi	35	39	hydroxychloroquine	hydroxychloroquine	NN
cord-272015-1anph6qi	35	40	,	,	,
cord-272015-1anph6qi	35	41	azithromycin	azithromycin	NNP
cord-272015-1anph6qi	35	42	,	,	,
cord-272015-1anph6qi	35	43	and	and	CC
cord-272015-1anph6qi	35	44	combination	combination	NN
cord-272015-1anph6qi	35	45	in	in	IN
cord-272015-1anph6qi	35	46	patients	patient	NNS
cord-272015-1anph6qi	35	47	hospitalized	hospitalize	VBN
cord-272015-1anph6qi	35	48	with	with	IN
cord-272015-1anph6qi	35	49	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	35	50	The	the	DT
cord-272015-1anph6qi	35	51	association	association	NN
cord-272015-1anph6qi	35	52	of	of	IN
cord-272015-1anph6qi	35	53	treatment	treatment	NN
cord-272015-1anph6qi	35	54	with	with	IN
cord-272015-1anph6qi	35	55	hydroxychloroquine	hydroxychloroquine	NN
cord-272015-1anph6qi	35	56	and	and	CC
cord-272015-1anph6qi	35	57	hospital	hospital	NN
cord-272015-1anph6qi	35	58	mortality	mortality	NN
cord-272015-1anph6qi	35	59	in	in	IN
cord-272015-1anph6qi	35	60	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	35	61	patients	patient	NNS
cord-272015-1anph6qi	35	62	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-272015-1anph6qi	35	63	:	:	:
cord-272015-1anph6qi	35	64	from	from	IN
cord-272015-1anph6qi	35	65	malaria	malaria	NN
cord-272015-1anph6qi	35	66	to	to	IN
cord-272015-1anph6qi	35	67	autoimmunity	autoimmunity	NN
cord-272015-1anph6qi	35	68	Lupus	Lupus	NNP
cord-272015-1anph6qi	35	69	Anticoagulant	Anticoagulant	NNP
cord-272015-1anph6qi	35	70	and	and	CC
cord-272015-1anph6qi	35	71	Abnormal	abnormal	JJ
cord-272015-1anph6qi	35	72	Coagulation	coagulation	NN
cord-272015-1anph6qi	35	73	Tests	test	NNS
cord-272015-1anph6qi	35	74	in	in	IN
cord-272015-1anph6qi	35	75	Patients	patient	NNS
cord-272015-1anph6qi	35	76	with	with	IN
cord-272015-1anph6qi	35	77	Covid-19	Covid-19	NNP
cord-272015-1anph6qi	35	78	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-272015-1anph6qi	35	79	Use	Use	NNP
cord-272015-1anph6qi	36	1	Is	be	VBZ
cord-272015-1anph6qi	36	2	Associated	associate	VBN
cord-272015-1anph6qi	36	3	with	with	IN
cord-272015-1anph6qi	36	4	Lower	low	JJR
cord-272015-1anph6qi	36	5	Odds	odd	NNS
cord-272015-1anph6qi	36	6	of	of	IN
cord-272015-1anph6qi	36	7	Persistently	persistently	RB
cord-272015-1anph6qi	36	8	Positive	Positive	NNP
cord-272015-1anph6qi	36	9	Antiphospholipid	Antiphospholipid	NNP
cord-272015-1anph6qi	36	10	Antibodies	Antibodies	NNPS
cord-272015-1anph6qi	36	11	and/or	and/or	CC
cord-272015-1anph6qi	36	12	Lupus	Lupus	NNP
cord-272015-1anph6qi	36	13	Anticoagulant	Anticoagulant	NNP
cord-272015-1anph6qi	36	14	in	in	IN
cord-272015-1anph6qi	36	15	Systemic	Systemic	NNP
cord-272015-1anph6qi	36	16	Lupus	Lupus	NNP
cord-272015-1anph6qi	36	17	Erythematosus	Erythematosus	NNP
cord-272015-1anph6qi	36	18	Low	low	JJ
cord-272015-1anph6qi	36	19	-	-	HYPH
cord-272015-1anph6qi	36	20	dose	dose	NN
cord-272015-1anph6qi	36	21	hydroxychloroquine	hydroxychloroquine	NN
cord-272015-1anph6qi	36	22	therapy	therapy	NN
cord-272015-1anph6qi	36	23	and	and	CC
cord-272015-1anph6qi	36	24	mortality	mortality	NN
cord-272015-1anph6qi	36	25	in	in	IN
cord-272015-1anph6qi	36	26	hospitalised	hospitalise	VBN
cord-272015-1anph6qi	36	27	patients	patient	NNS
cord-272015-1anph6qi	36	28	with	with	IN
cord-272015-1anph6qi	36	29	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	36	30	:	:	:
cord-272015-1anph6qi	36	31	a	a	DT
cord-272015-1anph6qi	36	32	nationwide	nationwide	JJ
cord-272015-1anph6qi	36	33	observational	observational	JJ
cord-272015-1anph6qi	36	34	study	study	NN
cord-272015-1anph6qi	36	35	of	of	IN
cord-272015-1anph6qi	36	36	8075	8075	CD
cord-272015-1anph6qi	36	37	participants	participant	NNS
cord-272015-1anph6qi	36	38	Use	Use	NNP
cord-272015-1anph6qi	36	39	of	of	IN
cord-272015-1anph6qi	36	40	hydroxychloroquine	hydroxychloroquine	NN
cord-272015-1anph6qi	36	41	in	in	IN
cord-272015-1anph6qi	36	42	hospitalised	hospitalise	VBN
cord-272015-1anph6qi	36	43	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	36	44	patients	patient	NNS
cord-272015-1anph6qi	36	45	is	be	VBZ
cord-272015-1anph6qi	36	46	associated	associate	VBN
cord-272015-1anph6qi	36	47	with	with	IN
cord-272015-1anph6qi	36	48	reduced	reduce	VBN
cord-272015-1anph6qi	36	49	mortality	mortality	NN
cord-272015-1anph6qi	36	50	:	:	:
cord-272015-1anph6qi	36	51	Findings	finding	NNS
cord-272015-1anph6qi	36	52	from	from	IN
cord-272015-1anph6qi	36	53	the	the	DT
cord-272015-1anph6qi	36	54	observational	observational	JJ
cord-272015-1anph6qi	36	55	multicentre	multicentre	NN
cord-272015-1anph6qi	37	1	Italian	italian	JJ
cord-272015-1anph6qi	37	2	CORIST	CORIST	NNP
cord-272015-1anph6qi	37	3	study	study	NN
cord-272015-1anph6qi	38	1	An	an	DT
cord-272015-1anph6qi	38	2	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	38	3	cytokine	cytokine	NN
cord-272015-1anph6qi	38	4	signature	signature	NN
cord-272015-1anph6qi	38	5	predicts	predict	VBZ
cord-272015-1anph6qi	38	6	COVID-19	covid-19	JJ
cord-272015-1anph6qi	38	7	severity	severity	NN
cord-272015-1anph6qi	38	8	and	and	CC
cord-272015-1anph6qi	38	9	survival	survival	NN
cord-272015-1anph6qi	38	10	Longterm	Longterm	NNP
cord-272015-1anph6qi	38	11	hydroxychloroquine	hydroxychloroquine	NN
cord-272015-1anph6qi	38	12	use	use	NN
cord-272015-1anph6qi	38	13	in	in	IN
cord-272015-1anph6qi	38	14	patients	patient	NNS
cord-272015-1anph6qi	38	15	with	with	IN
cord-272015-1anph6qi	38	16	rheumatic	rheumatic	JJ
cord-272015-1anph6qi	38	17	conditions	condition	NNS
cord-272015-1anph6qi	38	18	and	and	CC
cord-272015-1anph6qi	38	19	development	development	NN
cord-272015-1anph6qi	38	20	of	of	IN
cord-272015-1anph6qi	38	21	SARS	SARS	NNP
cord-272015-1anph6qi	38	22	-	-	HYPH
cord-272015-1anph6qi	38	23	CoV-2	CoV-2	NNP
cord-272015-1anph6qi	38	24	infection	infection	NN
cord-272015-1anph6qi	38	25	:	:	:
cord-272015-1anph6qi	38	26	a	a	DT
cord-272015-1anph6qi	38	27	retrospective	retrospective	JJ
cord-272015-1anph6qi	38	28	cohort	cohort	NN
cord-272015-1anph6qi	38	29	study	study	NN
cord-272015-1anph6qi	39	1	Chloroquine	Chloroquine	NNP
cord-272015-1anph6qi	39	2	inhibits	inhibit	VBZ
cord-272015-1anph6qi	39	3	the	the	DT
cord-272015-1anph6qi	39	4	release	release	NN
cord-272015-1anph6qi	39	5	of	of	IN
cord-272015-1anph6qi	39	6	inflammatory	inflammatory	JJ
cord-272015-1anph6qi	39	7	cytokines	cytokine	NNS
cord-272015-1anph6qi	39	8	by	by	IN
cord-272015-1anph6qi	39	9	human	human	JJ
cord-272015-1anph6qi	39	10	lung	lung	NN
cord-272015-1anph6qi	39	11	explants	explant	NNS
cord-272015-1anph6qi	39	12	Mortality	Mortality	NNP
cord-272015-1anph6qi	39	13	in	in	IN
cord-272015-1anph6qi	39	14	COVID-19	covid-19	JJ
cord-272015-1anph6qi	39	15	patients	patient	NNS
cord-272015-1anph6qi	39	16	with	with	IN
cord-272015-1anph6qi	39	17	acute	acute	JJ
cord-272015-1anph6qi	39	18	respiratory	respiratory	JJ
cord-272015-1anph6qi	39	19	distress	distress	NN
cord-272015-1anph6qi	39	20	syndrome	syndrome	NN
cord-272015-1anph6qi	39	21	and	and	CC
cord-272015-1anph6qi	39	22	corticosteroids	corticosteroid	NNS
cord-272015-1anph6qi	39	23	use	use	VBP
cord-272015-1anph6qi	39	24	:	:	:
cord-272015-1anph6qi	39	25	a	a	DT
cord-272015-1anph6qi	39	26	systematic	systematic	JJ
cord-272015-1anph6qi	39	27	review	review	NN
cord-272015-1anph6qi	39	28	and	and	CC
cord-272015-1anph6qi	39	29	meta	meta	NNP
cord-272015-1anph6qi	39	30	-	-	HYPH
cord-272015-1anph6qi	39	31	analysis	analysis	NN
cord-272015-1anph6qi	40	1	Chloroquine	Chloroquine	NNP
cord-272015-1anph6qi	40	2	inhibits	inhibit	VBZ
cord-272015-1anph6qi	40	3	production	production	NN
cord-272015-1anph6qi	40	4	of	of	IN
cord-272015-1anph6qi	40	5	TNF	TNF	NNP
cord-272015-1anph6qi	40	6	-	-	HYPH
cord-272015-1anph6qi	40	7	α	α	NNP
cord-272015-1anph6qi	40	8	,	,	,
cord-272015-1anph6qi	40	9	IL-1β	IL-1β	NNP
cord-272015-1anph6qi	40	10	and	and	CC
cord-272015-1anph6qi	40	11	IL-6	IL-6	NNP
cord-272015-1anph6qi	40	12	from	from	IN
cord-272015-1anph6qi	41	1	lipopolysaccharide	lipopolysaccharide	NN
cord-272015-1anph6qi	41	2	-	-	HYPH
cord-272015-1anph6qi	41	3	stimulated	stimulate	VBN
cord-272015-1anph6qi	41	4	human	human	JJ
cord-272015-1anph6qi	41	5	monocytes	monocyte	NNS
cord-272015-1anph6qi	41	6	/	/	SYM
cord-272015-1anph6qi	41	7	macrophages	macrophage	NNS
cord-272015-1anph6qi	41	8	by	by	IN
cord-272015-1anph6qi	41	9	different	different	JJ
cord-272015-1anph6qi	41	10	modes	mode	NNS
cord-272015-1anph6qi	41	11	Early	Early	NNP
cord-272015-1anph6qi	41	12	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-272015-1anph6qi	41	13	but	but	CC
cord-272015-1anph6qi	41	14	not	not	RB
cord-272015-1anph6qi	41	15	Chloroquine	Chloroquine	NNP
cord-272015-1anph6qi	41	16	use	use	NN
cord-272015-1anph6qi	41	17	reduces	reduce	VBZ
cord-272015-1anph6qi	41	18	ICU	ICU	NNP
cord-272015-1anph6qi	41	19	admission	admission	NN
cord-272015-1anph6qi	41	20	in	in	IN
cord-272015-1anph6qi	41	21	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	41	22	patients	patient	NNS
cord-272015-1anph6qi	41	23	High	high	JJ
cord-272015-1anph6qi	41	24	incidence	incidence	NN
cord-272015-1anph6qi	41	25	of	of	IN
cord-272015-1anph6qi	41	26	venous	venous	JJ
cord-272015-1anph6qi	41	27	thromboembolic	thromboembolic	JJ
cord-272015-1anph6qi	41	28	events	event	NNS
cord-272015-1anph6qi	41	29	in	in	IN
cord-272015-1anph6qi	41	30	anticoagulated	anticoagulated	JJ
cord-272015-1anph6qi	41	31	severe	severe	JJ
cord-272015-1anph6qi	41	32	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	41	33	patients	patient	NNS
cord-272015-1anph6qi	41	34	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-272015-1anph6qi	41	35	use	use	VB
cord-272015-1anph6qi	41	36	against	against	IN
cord-272015-1anph6qi	41	37	SARS	SARS	NNP
cord-272015-1anph6qi	41	38	-	-	HYPH
cord-272015-1anph6qi	41	39	CoV-2	CoV-2	NNP
cord-272015-1anph6qi	41	40	infection	infection	NN
cord-272015-1anph6qi	41	41	in	in	IN
cord-272015-1anph6qi	41	42	non	non	JJ
cord-272015-1anph6qi	41	43	-	-	JJ
cord-272015-1anph6qi	41	44	human	human	JJ
cord-272015-1anph6qi	41	45	primates	primate	NNS
cord-272015-1anph6qi	41	46	Colchicine	Colchicine	NNP
cord-272015-1anph6qi	41	47	as	as	IN
cord-272015-1anph6qi	41	48	a	a	DT
cord-272015-1anph6qi	41	49	possible	possible	JJ
cord-272015-1anph6qi	41	50	therapeutic	therapeutic	JJ
cord-272015-1anph6qi	41	51	option	option	NN
cord-272015-1anph6qi	41	52	in	in	IN
cord-272015-1anph6qi	41	53	COVID-19	COVID-19	NNP
cord-272015-1anph6qi	41	54	infection	infection	NN
cord-272015-1anph6qi	41	55	Selective	selective	JJ
cord-272015-1anph6qi	41	56	regulation	regulation	NN
cord-272015-1anph6qi	41	57	of	of	IN
cord-272015-1anph6qi	41	58	cytokine	cytokine	JJ
cord-272015-1anph6qi	41	59	secretion	secretion	NN
cord-272015-1anph6qi	41	60	by	by	IN
cord-272015-1anph6qi	41	61	hydroxychloroquine	hydroxychloroquine	NN
cord-272015-1anph6qi	41	62	:	:	:
cord-272015-1anph6qi	41	63	inhibition	inhibition	NN
cord-272015-1anph6qi	41	64	of	of	IN
cord-272015-1anph6qi	41	65	interleukin	interleukin	NN
cord-272015-1anph6qi	41	66	1	1	CD
cord-272015-1anph6qi	41	67	alpha	alpha	NN
cord-272015-1anph6qi	41	68	(	(	-LRB-
cord-272015-1anph6qi	41	69	IL-1-alpha	IL-1-alpha	''
cord-272015-1anph6qi	41	70	)	)	-RRB-
cord-272015-1anph6qi	41	71	and	and	CC
cord-272015-1anph6qi	41	72	IL-6	IL-6	NNP
cord-272015-1anph6qi	41	73	in	in	IN
cord-272015-1anph6qi	41	74	human	human	JJ
cord-272015-1anph6qi	41	75	monocytes	monocyte	NNS
cord-272015-1anph6qi	41	76	and	and	CC
cord-272015-1anph6qi	41	77	T	t	NN
cord-272015-1anph6qi	41	78	cells	cell	NNS
cord-272015-1anph6qi	41	79	Effect	effect	NN
cord-272015-1anph6qi	41	80	of	of	IN
cord-272015-1anph6qi	41	81	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-272015-1anph6qi	41	82	in	in	IN
cord-272015-1anph6qi	41	83	Hospitalized	Hospitalized	NNP
cord-272015-1anph6qi	41	84	Patients	Patients	NNP
cord-272015-1anph6qi	41	85	with	with	IN
cord-272015-1anph6qi	41	86	Covid-19	Covid-19	NNP
cord-272015-1anph6qi	41	87	Clinical	clinical	JJ
cord-272015-1anph6qi	41	88	criteria	criterion	NNS
cord-272015-1anph6qi	41	89	for	for	IN
cord-272015-1anph6qi	41	90	COVID-19-associated	COVID-19-associated	NNP
cord-272015-1anph6qi	41	91	hyperinflammatory	hyperinflammatory	NNP
cord-272015-1anph6qi	41	92	syndrome	syndrome	NN
cord-272015-1anph6qi	41	93	:	:	:
cord-272015-1anph6qi	41	94	a	a	DT
cord-272015-1anph6qi	41	95	cohort	cohort	NN
cord-272015-1anph6qi	41	96	study	study	NN
cord-272015-1anph6qi	41	97	World	World	NNP
cord-272015-1anph6qi	41	98	Health	Health	NNP
cord-272015-1anph6qi	41	99	Organization	Organization	NNP
cord-272015-1anph6qi	41	100	Extrafollicular	Extrafollicular	NNP
cord-272015-1anph6qi	41	101	B	B	NNP
cord-272015-1anph6qi	41	102	cell	cell	NN
cord-272015-1anph6qi	41	103	responses	response	NNS
cord-272015-1anph6qi	41	104	correlate	correlate	VBP
cord-272015-1anph6qi	41	105	with	with	IN
cord-272015-1anph6qi	41	106	neutralizing	neutralize	VBG
cord-272015-1anph6qi	41	107	antibodies	antibody	NNS
cord-272015-1anph6qi	41	108	and	and	CC
cord-272015-1anph6qi	41	109	morbidity	morbidity	NN
cord-272015-1anph6qi	41	110	in	in	IN
cord-272015-1anph6qi	41	111	COVID-19	COVID-19	NNP